In vivo quantification of ERb expression by pharmacokinetic modeling: Studies with18F-FHNP PET

Journal of Nuclear Medicine

Volumn 58, Issue 11, 2017, Pages 1743-1748

  Antunes, Inês F ^a   Willemsen, Antoon T M ^a   Sijbesma, Jurgen W A ^a   Boerema, Ate S ^a,b   Van Waarde, Aren ^a   Glaudemans, Andor W J M ^a   Dierckx, Rudi A J O ^a   De Vries, Elisabeth G E ^a   Hospers, Geke A P ^a   De Vries, Erik F J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Estrogen receptors; Oncology; PET; Pharmacokinetics; Quantification

Indexed keywords

2 FLUORO 6 (6 HYDROXYNAPHTHALEN 2 YL)PYRIDIN 3 OL F 18; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; TRACER; UNCLASSIFIED DRUG; 2-FLUORO-6-(6-HYDROXYNAPHTHALEN-2-YL)PYRIDIN-3-OL; NAPHTHOL DERIVATIVE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG SYNTHESIS; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VIVO STUDY; MALE; METABOLIC RATE; METABOLITE; NONHUMAN; NUDE RAT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SK-OV-3 CELL LINE; TUMOR VOLUME; WESTERN BLOTTING; AGONISTS; ANIMAL; BIOSYNTHESIS; DIAGNOSTIC IMAGING; GENETICS; IMAGE PROCESSING; OVARY TUMOR; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR BETA; FEMALE; GENISTEIN; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MODELS, STATISTICAL; NAPHTHOLS; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RATS; RATS, NUDE; REPRODUCIBILITY OF RESULTS;

EID: 85032839103     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.117.192666     Document Type: Article

References (18)

1. Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor b ligands: recent advances and biomedical applications. Med Res Rev. 2011;31:364–442.
2. Fox EM, Davis RJ, Shupnik MA. ERb in breast cancer: onlooker, passive player, or active protector? Steroids. 2008;73:1039–1051.
3. Yan Y, Li X, Blanchard A, et al. Expression of both estrogen receptor-beta 1 (ER-b) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-a)negative early breast cancer (EBC). Ann Oncol. 2013;24:1986–1993.
4. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastu-zumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007;102:43–49.
5. Smith IE, Walsh G, Skene A, et al. A phase II placebo-controlled trial of neo-adjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25:3816–3822.
6. van Kruchten M, Glaudemans AWJM, de Vries EFJ, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;53:182–190.
7. Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. 2008;14:4417–4426.
8. Ikeda K, Shiraishi K, Yoshida A, et al. Synchronous multiple lung adenocarci-nomas: estrogen concentration in peripheral lung. PLoS One. 2016;11:e0160910.
9. Antunes IF, van Waarde A, Dierckx RA, de Vries EGE, Hospers GAP, de Vries EF. Synthesis and evaluation of the new estrogen receptor b selective radioligand [18F]FHNP: comparison with [18F]FES. J Nucl Med. 2017;58:554–559.
10. Khayum MA, de Vries EFJ, Glaudemans AWJM, Dierckx RAJO, Doorduin J. In vivo imaging of brain estrogen receptors in rats: a 16a-18F-fluoro-17b-estradiol PET study. J Nucl Med. 2014;55:481–487.
11. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1–7.
12. Glatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys. 2007;34:4285–4292.
13. Elebro K, Borgquist S, Rosendahl AH, et al. High estrogen receptor b expression is prognostic among adjuvant chemotherapy–treated patients: results from a population-based breast cancer cohort. Clin Cancer Res. 2017;23:766–777.
14. Yoo J, Dence CS, Sharp TL, Katzenellenbogen JA, Welch MJ. Synthesis of an estrogen receptor b-selective radioligand: 5-[18F]fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16a-[18F]fluoro-17b-estradiol. J Med Chem. 2005;48:6366–6378.
15. Lee JH, Peters O, Lehmann L, et al. Synthesis and biological evaluation of two agents for imaging estrogen receptor b by positron emission tomography: challenges in PET imaging of a low abundance target. Nucl Med Biol. 2012;39:1105–1116.
16. Tewson TJ, Mankoff DA, Peterson LM, Woo I, Petra P. Interactions of 16a-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999;26:905–913.
17. Beattie BJ, Smith-Jones PM, Jhanwar YS, et al. Pharmacokinetic assessment of the uptake of 16b-18F-fuoro-5a-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010;51:183–192.
18. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol. 1997;24:341–348.